VIP
Status
No approved product. No FDA-approved labeling exists for vasoactive intestinal peptide for any indication. Preparations used clinically are compounded and are not FDA-reviewed.
What it is
Vasoactive intestinal peptide, studied for inflammation and nasal use.
What published research measured
A 28-amino-acid neuropeptide with broad physiological roles including vasodilation, bronchodilation, and immune and secretory regulation. Its therapeutic development has focused on pulmonary arterial hypertension and sarcoidosis, where inhaled formulations have been studied in small trials with mixed results. Intranasal use for chronic inflammatory response syndrome, the context in which it most often appears outside conventional medicine, rests on a clinical protocol rather than on randomized trial evidence, and no controlled trial supports that indication. The pharmacology imposes real limits: VIP has a half-life of about a minute in circulation, and its vasodilatory potency means hypotension and flushing are dose-limiting.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.